CTOs on the Move

Mabtech Inc

www.mabtech.com

 
Mabtech Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.mabtech.com
  • 3814 West St Ste 112
    Cincinnati, OH USA 45227
  • Phone: 513.871.4500

Executives

Name Title Contact Details

Similar Companies

SQZ Biotech

SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.

Inozyme

We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

Telstar

Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.